The REFLECT Trial: A Randomized Evaluation oF the TriGuard HDH Cerebral Embolic Protection Device and the TriGUARD 3 Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation

Recruiting
99 years or below
All
Phase 2
40 participants needed

Brief description of study

This is a research study designed to look at the safety and effectiveness of the TriGUARD 3 cerebral embolic protection device in patients undergoing transcatheter aortic valve implantation (TAVI). The purpose of the study is to assess whether the TriGUARD 3 can prevent death, stroke, more subtle signs of brain injury, and/or silent brain injury as measured by a magnetic resonance imaging (MRI) study of the brain.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cerebral Embolic Lesion
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 830258

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.